New cancer pill tested in patients who ran out of options
NCT ID NCT03510104
Summary
This first-in-human study tested a new oral medication called MRX-2843 in adults with advanced solid tumors that had returned or stopped responding to standard treatments. The main goals were to find the highest safe dose and understand how the drug moves through the body. Researchers enrolled 42 participants to carefully monitor side effects and determine if the drug shows enough promise for further testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.